Kitted assays for clinical laboratories streamline the
detection of challenging genes and variants to improve results for
underrepresented populations
MINNEAPOLIS ,
Nov. 2,
2023 /PRNewswire/ -- Bio-Techne Corporation
(NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand,
will present new data on clinical laboratory testing solutions
related to cystic fibrosis variant detection, cancer monitoring,
resolving conventionally inaccessible, disease-causing genes, and
more at the upcoming meeting of the Association for Molecular
Pathology (AMP), to be held November
14-18 in Salt Lake City,
Utah. Attendees can learn about Asuragen's new products and
innovations through a series of corporate workshops and poster
presentations.
"We are excited to connect with the innovative and dedicated AMP
community as we all seek to improve clinical laboratory
capabilities to deliver the best possible results for patients,"
said Bernard Andruss, PhD, Vice
President and General Manager, Molecular Diagnostics Division,
Bio-Techne. "We look forward to sharing new data that reinforces
our commitment to more equitable healthcare, comprehensive genetic
coverage, and novel approaches to cancer monitoring and
management."
In addition, Dr. Jordan Laser,
Senior Director, Clinical and Medical Affairs for Bio-Techne's
Diagnostics and Genomics Segment, will be recognized at the
conference with the AMP Meritorious Service Award for his work to
promote AMP as a member of the association.
Poster Presentations
Impact of Variants of Varying Clinical Consequence in
Underrepresented Populations and Implications for a Minimum Variant
Set for Pan-Ancestry Cystic Fibrosis Carrier Screening
Presenter:
Brian
Haynes, PhD, CSO, Asuragen & Head of Bioinformatics
Molecular Diagnostics Division
Accurate Genotyping of Complex, Clinically-Relevant Variants in
11 Hard-to-Decipher Genes by Combining Novel PCR Chemistries with
Any-Length Nanopore Sequencing for Carrier Screening
Presenter: Brennan Greenlee,
MS, Sr. Research Associate, Asuragen
Development of a Novel Exosome-based, Multiplexed RT-qPCR
Technology for Rapid and Accurate Detection of Circulating Tumor
Acquired Resistance Variants in ESR1 at ≤ 0.1% Frequency
Presenter: Julie Thibert, MS,
Scientist, Asuragen
Prototype RT-qPCR PML:RARA Reagents and a Commercial PML-RARA
Kit Yield Highly Correlated Results
Presenter: Ila Wolf, PhD,
Scientist, Asuragen
Corporate Workshops
Simple, Sensitive, and Scalable: QuantideX® Suite of Assays for
Targeted MRD Monitoring of Leukemic Fusions November 15, 11:00
am, Room 251F
For highly sensitive detection of leukemic fusions using widely
available qPCR equipment, Asuragen's QuantideX qPCR BCR-ABL kits
offer IVD or RUO testing capabilities for molecular laboratories of
any size. Learn about key features of these assays and see
real-world performance data.
Speaker: Holli M. Drendel, Ph.
D., FACMGG
Director, Molecular Pathology Laboratory
Carolinas Pathology Group
AmplideX® to the Rescue: One easy-to-implement test
workflow enabling repeat expansion resolution, copy number
assessment, and highly multiplexed variant detection.
November 15, 12:00 pm, Room 251F
Asuragen's simple and scalable AmplideX technology, the gold
standard for FMR1 analysis, has been expanded to cover other
repeat disorder genes, copy number assays, and highly multiplexed
variant detection. This workshop will report the experience of a
clinical lab that adopted the AmplideX SMN1/2 Plus Kit for
detection of SMN1 and SMN2 copy numbers and genetic
variants.
Speaker: Sarah S. Murray, Ph.D.,
FACMG
Clinical
Professor, Department of Pathology
Director,
Medical Genetics and Genomics
University
of California San Diego
About Bio-Techne
Bio-Techne Corporation (NASDAQ:
TECH) is a global life sciences company providing innovative tools
and bioactive reagents for the research and clinical diagnostic
communities. Bio-Techne products assist scientific investigations
into biological processes and the nature and progress of specific
diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnoses. With thousands of
products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has
approximately 3,200 employees worldwide. For more information on
Bio-Techne and its brands, please visit https://www.bio-techne.com
or follow the Company on social media at: Facebook, LinkedIn,
Twitter or YouTube.
Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
Media Contact:
Suzanne Howard
suzanne@bioscribe.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/asuragen-to-present-novel-clinical-testing-data-at-amp-2023-conference-301975325.html
SOURCE Bio-Techne Corporation